Immunome Management
Management criteria checks 1/4
Immunome's CEO is Clay Siegall, appointed in Oct 2023, has a tenure of 1.17 years. total yearly compensation is $15.65M, comprised of 1% salary and 99% bonuses, including company stock and options. directly owns 0.83% of the company’s shares, worth $5.76M. The average tenure of the management team and the board of directors is 1.2 years and 3.5 years respectively.
Key information
Clay Siegall
Chief executive officer
US$15.6m
Total compensation
| CEO salary percentage | 1.0% |
| CEO tenure | 1.2yrs |
| CEO ownership | 0.8% |
| Management average tenure | 1.2yrs |
| Board average tenure | 3.5yrs |
Recent management updates
Recent updates
Immunome: A Recently Acquired Lead Asset And A Small Market
Dec 11Immunome: Why It Has Doubled Over The Last Month
Jan 18Will Immunome (NASDAQ:IMNM) Spend Its Cash Wisely?
Mar 17
Is Immunome (NASDAQ:IMNM) In A Good Position To Deliver On Growth Plans?
Nov 20Immunome GAAP EPS of -$0.74
Aug 05Here's Why We're Watching Immunome's (NASDAQ:IMNM) Cash Burn Situation
Aug 05Immunome gains 34% after preclinical data on COVID-19 antibody
Jun 30We Think Immunome (NASDAQ:IMNM) Can Afford To Drive Business Growth
Feb 21Companies Like Immunome (NASDAQ:IMNM) Are In A Position To Invest In Growth
Oct 02Immunome launches $27M private placement
Apr 26Do Institutions Own Immunome, Inc. (NASDAQ:IMNM) Shares?
Mar 12Read This Before Selling Immunome, Inc. (NASDAQ:IMNM) Shares
Jan 18CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$305m |
| Jun 30 2024 | n/a | n/a | -US$263m |
| Mar 31 2024 | n/a | n/a | -US$232m |
| Dec 31 2023 | US$16m | US$163k | -US$107m |
Compensation vs Market: Clay's total compensation ($USD15.65M) is above average for companies of similar size in the US market ($USD3.30M).
Compensation vs Earnings: Insufficient data to compare Clay's compensation with company performance.
CEO
Clay Siegall (63 yo)
1.2yrs
Tenure
US$15,648,944
Compensation
Dr. Clay B. Siegall, Ph D., serves as Independent Chairman since December 13, 2023 at Tourmaline Bio, Inc. He served as Chief Executive Officer & President of Morph Immune, Inc. from March 2023 until Octob...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1.2yrs | US$15.65m | 0.83% $ 5.8m | |
| Chief Scientific Officer | 1.2yrs | US$2.17m | 0.022% $ 149.9k | |
| Chief Medical Officer | 1.2yrs | US$3.22m | 0.025% $ 175.1k | |
| Executive VP of Operations | 1.2yrs | no data | 0.076% $ 526.0k | |
| Chief Technical Officer | no data | no data | 0.034% $ 232.6k | |
| Chief Legal Officer | 4.2yrs | US$1.64m | 0.0089% $ 61.6k | |
| Chief Strategy Officer | 1.2yrs | no data | 0.068% $ 468.7k | |
| Chief Business Officer | less than a year | no data | no data | |
| Executive Vice President of Commercial | less than a year | no data | no data |
1.2yrs
Average Tenure
51yo
Average Age
Experienced Management: IMNM's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1.2yrs | US$15.65m | 0.83% $ 5.8m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Director | 7yrs | US$59.23k | 0.63% $ 4.4m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Lead Independent Director | 1.2yrs | US$296.59k | 0.0083% $ 57.5k | |
| Independent Director | 1.2yrs | US$294.75k | 0% $ 0 | |
| Member of COVID-19 Advisory Board | 3.5yrs | no data | no data | |
| Independent Director | less than a year | no data | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of COVID-19 Advisory Board | 4.3yrs | no data | no data | |
| Member of COVID-19 Advisory Board | 4.3yrs | no data | no data | |
| Member of COVID-19 Advisory Board | 4.3yrs | no data | no data |
3.5yrs
Average Tenure
60yo
Average Age
Experienced Board: IMNM's board of directors are considered experienced (3.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 00:03 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Immunome, Inc. is covered by 9 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Lut Ming Cheng | Cantor Fitzgerald & Co. |
| Michael Schmidt | Guggenheim Securities, LLC |
| Lut Ming Cheng | J.P. Morgan |